REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIA ANTIBODIES

The present invention relates to reversal agents, which specifically bind to the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D as described in WO2013/167669, and neutralize the therapeutic activity of this anti-FXIa antibody, as well as to compositions comprising these reversal agents. Methods of obt...

Full description

Saved in:
Bibliographic Details
Main Authors WEBER, Ernst, WILMEN, Andreas
Format Patent
LanguageEnglish
French
German
Published 08.09.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to reversal agents, which specifically bind to the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D as described in WO2013/167669, and neutralize the therapeutic activity of this anti-FXIa antibody, as well as to compositions comprising these reversal agents. Methods of obtaining the antibodies or antigen-binding fragments thereof (such as Fab fragments) and nucleic acids encoding the same, are also provided. Furthermore, the invention relates to methods of use of these reversal agents, such as methods for neutralizing the therapeutic activity of the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D, and to related methods as essential part of a general bleeding management.
Bibliography:Application Number: EP20190798232